Literature DB >> 21328393

Prevalence of human T-cell lymphotropic virus type 1 and 2 among patients with malignant hematological diseases in south Chile.

Alejandro Barrientos1, Mauricio Lopez, Cristina Sotomayor, Lilian Pilleux, Susana Calderón, Maritza Navarrete, Carola Otth.   

Abstract

Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) are oncogenic retroviruses linked etiologically to human diseases. In Chile, these viruses have been studied in ethnic populations, or patients diagnosed clinically with HTLV-1 associated myelopathy/tropical spastic paraparesis, but have not been studied in patients with malignant hematological diseases. The aim of this study was to determine the seroprevalence and viral prevalence of HTLV-1/2 among patients with malignant hematological diseases. Eighty-eight patients with malignant hematological diseases were tested by enzyme-linked immunosorbent assay (ELISA) for IgG anti-HTLV-1/2 and nested-PCR for the tax gene. The seroprevalence by ELISA was 3.4% and the viral prevalence by nested-PCR tax was 18.2%. HTLV-1 was found in 17% and HTLV-2 in 1% of the patients tested. HTLV-1/2 was found in 17.4% of patients with non-Hodgkin's lymphomas, 28.6% of patients with Hodgkin's lymphomas, 80% of patients with chronic lymphocytic leukemia, 11.4% of patients with acute lymphoblastic leukemia, and 22.2% of patients with acute myeloid leukemia. A high prevalence of HTLV-1/2 was found in patients with malignant hematological diseases. A high proportion of patients were seronegative to HTLV-1/2 infection, similar to other HTLV-1/2 associated disorders. Because 50% of patients positive for HTLV-1/2 were below 30 years old, it is suggested that vertical transmission could have played an important role in these patients.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21328393     DOI: 10.1002/jmv.22015

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  First Description of Seronegative HTLV-1 Carriers in Argentina.

Authors:  Sandra Gallego; María C Frutos; Sebastián Blanco; Gonzalo Castro; Marcos Balangero; David Elías Panigo; Arnaldo Mangeaud; Carlos Remondegui; Anderson Santos Rocha; Gabriela Melo Franco; Marina Lobato Martins; Edel Figueiredo Barbosa-Stancioli; Silvia Nates
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

2.  Epidemiological analysis of HTLV-1 and HTLV-2 infection among different population in Central China.

Authors:  Yunyun Ma; Shangen Zheng; Na Wang; Yu Duan; Xinyu Sun; Jing Jin; Wenqiao Zang; Min Li; Yuanyuan Wang; Guoqiang Zhao
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

3.  Prevalence of Human T-Lymphotropic Virus Types I and II in Patients With Hematological Disorders in Isfahan, Iran.

Authors:  Mohammadreza Mahzounieh; Mohammadreza Ghorani; Ali Karimi; Batoul Pourgheysari; Razieh Nikoozad
Journal:  Jundishapur J Microbiol       Date:  2015-06-25       Impact factor: 0.747

4.  Relative frequency of Human T-cell Lymphotropic Virus I/II in HIV/AIDS patients.

Authors:  Mohsen Meidani; Nooshin Ahmadi; Bahareh Jamali; Zahra Askarian
Journal:  Adv Biomed Res       Date:  2014-01-09

5.  HTLV-2 infection in Manaus, Brazil: first description of HTLV-2c subtype in an urban area of the Western Amazon region.

Authors:  Gemilson Soares Pontes; Hygor Halyson Figueiredo Ribeiro; Diana Mota Toro; José Pereira de Moura Neto; Victor Souza; Maria Edilene Martins de Almeida; Valdinete Alves do Nascimento; Cristovão Alves da Costa; Felipe Gomes Naveca; Mike Santos; Antonio Carlos Rosário Vallinoto
Journal:  Rev Soc Bras Med Trop       Date:  2020-11-13       Impact factor: 1.581

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.